School of Medicine
Showing 251-260 of 739 Results
-
John P.A. Ioannidis
Professor of Medicine (Stanford Prevention Research Center), of Epidemiology and Population Health and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsMeta-research
Evidence-based medicine
Clinical and molecular epidemiology
Human genome epidemiology
Research design
Reporting of research
Empirical evaluation of bias in research
Randomized trials
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science -
Haruka Itakura, MD, PhD
Assistant Professor of Medicine (Oncology)
BioDr. Haruka Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine, a data scientist, and a practicing breast medical oncologist at the Stanford Women’s Cancer Center. She is board-certified in Oncology, Clinical Informatics, Hematology, and Internal Medicine. Her research mission is to drive medical advances at the intersection of cancer and data science, applying state-of-the-art machine learning/artificial intelligence techniques to extract clinically actionable knowledge from heterogeneous multi-scale cancer data to improve patient outcomes. Her ongoing research to develop robust methodologies and apply cutting-edge techniques to analyze complex cancer big data was catapulted by an NIH K01 Career Development Award in Biomedical Big Data Science after obtaining a PhD in Biomedical Informatics at Stanford University. Her cancer research focuses on extracting radiomic (pixel-level quantitative imaging) features of tumors from medical imaging studies and applying machine learning frameworks, including radiogenomic approaches, for the integrative analysis of heterogeneous, multi-omic (e.g., radiomic, genomic, transcriptomic) data to accelerate discoveries in cancer diagnostics and therapeutics. Her current projects include prediction modeling of survival, treatment response, recurrence, and CNS metastasis in different cancer subtypes; detection of occult invasive breast cancer; and identification of novel therapeutic targets. Her ultimate goal is to be able to translate her research findings back to the clinical setting for the benefit of patients with difficult-to-treat cancers.
-
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Current Research and Scholarly InterestsCell cycle and cyclin control of DNA replication .
-
Sneha Shah Jain MD, MBA
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Sneha S. Jain is a Clinical Assistant Professor of Medicine in the Division of Cardiovascular Medicine and Director of the GUIDE-AI Lab. She specializes in general cardiovascular medicine and preventive cardiology.
Dr. Jain pursued her undergraduate degree in Economics at Duke University and graduated with distinction. She received her medical degree from the Johns Hopkins School of Medicine and her MBA from Harvard Business School. She completed internal medicine residency training at Columbia/NewYork-Presbyterian, and fellowship training in cardiovascular medicine at Stanford University.
Her research focuses on the development and responsible evaluation of AI tools to augment healthcare delivery and improve patient outcomes. She works with the Data Science Team at Stanford Healthcare and the Stanford Center for Clinical Research to deploy and prospectively evaluate AI solutions across the healthcare enterprise. She serves on the American College of Cardiology Healthcare Innovation Section leadership council, the American Heart Association Expert Panel for the AI Validation Lab, and as an Expert AI consultant for the Journal of the American College of Cardiology. -
Siddhartha Jaiswal
Associate Professor of Pathology
Current Research and Scholarly InterestsWe identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.
